Tumor News and Research

RSS

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.

27 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Novel technique allows scientists to assay tumor invasion attributable to interstitial fluid

There are many factors that affect tumor invasion, the process where a tumor grows beyond the tissue where it first developed. While factors like genetics, tissue type and environmental exposure affect tumor metastasis and invasion, physical forces like fluid flow remain a poorly understood component of tumor invasion. A new video article in JoVE, the Journal of Visualized Experiments, describes a novel procedure that allows researchers to study and test the microenvironment of a growing tumor.

26 Jul 2012

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer.

26 Jul 2012

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

Karyopharm commences two KPT-330 phase 1 studies in cancers

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

25 Jul 2012

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

Seventeen National Institutes of Health grants are aimed at creating 3-D chips with living cells and tissues that accurately model the structure and function of human organs such as the lung, liver and heart. Once developed, these tissue chips will be tested with compounds known to be safe or toxic in humans to help identify the most reliable drug safety signals - ultimately advancing research to help predict the safety of potential drugs in a faster, more cost-effective way.

25 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.

25 Jul 2012

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor.

25 Jul 2012

New tool uses fluorescence to distinguish cancerous tissue from normal one in low-grade tumors

A new probe developed collaboratively at Norris Cotton Cancer Center and Dartmouth College's Thayer School of Engineering uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue from normal tissue. The probe tool, now already in use at the Cancer Center for brain surgery, may one day be used for surgeries for a variety of cancers.

25 Jul 2012

RhoC gene promotes breast cancer stem cell progression

Researchers at the University of Michigan Comprehensive Cancer Center have found that a cancer gene linked to aggressive spread of the disease promotes breast cancer stem cells. The finding implies a new way to target the behavior of these lethal cells.

25 Jul 2012

Tumor News and Research

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Fusion of FGFR and TACC gene leads to glioblastoma

Novel technique allows scientists to assay tumor invasion attributable to interstitial fluid

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

Karyopharm commences two KPT-330 phase 1 studies in cancers

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

MASL protein from plant's seeds may halt spread of melanoma

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

New tool uses fluorescence to distinguish cancerous tissue from normal one in low-grade tumors

RhoC gene promotes breast cancer stem cell progression

Hypoxic lung environment increases HIF-2a tumor growth signaling

Colonoscopy with polypectomy decreases colorectal cancer incidence and mortality

New large animal model for human cancer studies

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News